The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. ⋯ The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin (FL). Oxaliplatin improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus oxaliplatin in the postoperative adjuvant setting. ⋯ Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
A comparison of albumin and saline for fluid resuscitation in the intensive care unit.
ICU resuscitation with either normal saline or 4% albumin results in similar outcomes, in the absence of traumatic brain injury.
pearl